智通财经5月22日电，从业内获悉，上交所日前向各会员单位通报了2024年度会员投资者教育和保护工 作评选结果。东方财富、东莞证券、东吴证券、国联民生、华福证券、华泰证券、西部证券、湘财证 券、兴业证券和中泰证券10家券商获评"2024年度投资者教育优秀会员"。 (中证金牛座) 上交所2024年度会员投教工作评选结果出炉 ...

金十数据5月22日讯，上交所日前向各会员单位通报了2024年度会员投资者教育和保护工作评选结果。 东方财富、东莞证券、东吴证券、国联民生、华福证券、华泰证券、西部证券、湘财证券、兴业证券和 中泰证券10家券商获评"2024年度投资者教育优秀会员"（排名不分先后，下同）。 （中证金牛座） 上交所2024年度会员投教工作评选结果出炉，十家券商获评优秀 ...

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several securities firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is a misleading narrative driven by "restless capital" [2][11]. Summary by Sections Company Background - Huaxi Biological, once a darling of the capital market, saw its stock peak at 313.1 yuan and market capitalization exceed 150 billion yuan, but has since experienced a significant decline, with its stock price dropping to 52.61 yuan and market cap to 25.3 billion yuan as of May 21 [3][12]. Market Dynamics - The rise of recombinant collagen protein companies like Juzhi Biological and Jinbo Biological has shifted capital focus, with these companies achieving record highs in stock prices [4][14]. - Huaxi Biological's performance has been declining, particularly in its functional skincare segment, while the recombinant collagen protein sector is experiencing rapid growth [4][20]. Securities Firms' Reports - Huaxi Biological criticized reports from nine securities firms that favor recombinant collagen over hyaluronic acid, claiming these reports mislead the market [6][9]. - Specific reports from Huatai Securities, Guojin Securities, and others highlighted the advantages of recombinant collagen, such as its biological features and safety, which Huaxi disputes [7][8]. Industry Trends - The market for recombinant collagen products in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [12]. - Huaxi Biological's sales of hyaluronic acid accounted for 44% of the global market in 2021, but its revenue has been declining due to challenges in its functional skincare business [12][17]. Financial Performance - Huaxi Biological's revenue and net profit have been declining, with 2023 revenue at 6.08 billion yuan and a net profit of 593 million yuan, reflecting a year-on-year decrease of 4.45% and 38.97%, respectively [17][18]. - The company's functional skincare revenue peaked in 2022 but has since dropped, leading to overall performance issues [17][19]. Strategic Response - In response to declining performance, Huaxi Biological is restructuring its management and focusing on core competencies, including a shift in branding and operational strategies [19][20]. - The company has also made acquisitions to enter the collagen market, although its recent acquisition has not yet proven profitable [20]. Competitive Landscape - The article notes that both hyaluronic acid and recombinant collagen have their respective advantages, with hyaluronic acid still holding a competitive edge in certain applications despite market challenges [21].

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several brokerage firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is a misleading narrative driven by "restless capital" [1][9]. Group 1: Company Performance - Huaxi Biological's stock price peaked at 313.1 yuan with a market value exceeding 150 billion yuan, but as of May 21, it has plummeted to 52.61 yuan, with a market value of only 25.3 billion yuan, representing a loss of over 120 billion yuan in market capitalization [2][10]. - The company's revenue for 2023 and 2024 was 6.076 billion yuan and 5.371 billion yuan, respectively, showing a year-on-year decline of 4.45% and 11.61% [14]. - The net profit attributable to shareholders for the same years was 593 million yuan and 174 million yuan, reflecting a significant decline of 38.97% and 70.59% [14]. Group 2: Market Dynamics - The market is witnessing a shift in focus from hyaluronic acid to recombinant collagen protein, with companies like Juzhi Biological and Jinbo Biological experiencing significant stock price increases and strong revenue growth [12][17]. - The recombinant collagen protein market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [9]. Group 3: Industry Comparison - Huaxi Biological argues that the claims made by brokerage reports regarding the superiority of recombinant collagen protein over hyaluronic acid are misleading and lack scientific backing [5][18]. - Both hyaluronic acid and recombinant collagen protein have their respective advantages in different applications, with hyaluronic acid still holding competitive strength due to its established market presence [18]. Group 4: Company Strategy - In response to declining performance, Huaxi Biological is restructuring its management and focusing on core competencies, including a renewed emphasis on its strengths in hyaluronic acid [16]. - The company has also made strategic acquisitions, such as a 51% stake in Beijing Yierkang Biological Engineering, to enter the animal-derived collagen protein market, although this subsidiary reported losses in 2024 [17].

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several brokerage firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is misleading and driven by "restless capital" [1][7]. Company Overview - Huaxi Biological specializes in hyaluronic acid-related products and has faced significant stock price and market capitalization declines since reaching a peak in July 2021, with its stock price dropping from 313.1 yuan to 52.61 yuan as of May 21, 2023, resulting in a market cap reduction from over 1500 billion yuan to 253 billion yuan [2][8]. - The company has reported continuous revenue declines, with revenues of 60.76 billion yuan and 53.71 billion yuan for 2023 and 2024, respectively, representing year-on-year decreases of 4.45% and 11.61% [10]. Industry Dynamics - The market has seen a shift in focus towards recombinant collagen protein, with companies like Juzhi Biological and Jinbo Biological experiencing significant stock price increases and revenue growth, contrasting with Huaxi's struggles [2][13]. - The recombinant collagen protein market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 585.7 billion yuan by 2025 [7]. Performance Comparison - Juzhi Biological's revenues for 2022, 2023, and 2024 were 23.75 billion yuan, 35.26 billion yuan, and 55.39 billion yuan, respectively, with year-on-year growth rates around 50% [13]. - Jinbo Biological's revenues during the same period were 3.9 billion yuan, 7.8 billion yuan, and 14.43 billion yuan, with growth rates of 67.15%, 99.97%, and 84.92% [13]. Regulatory and Market Response - Huaxi Biological has reported the brokerage firms to the China Securities Regulatory Commission for allegedly misleading reports that could distort market perceptions [1][3]. - The company has emphasized the need for a healthy industry ecosystem and has engaged with industry associations to advocate for a return to scientific principles in the market [5][7].

Group 1 - Multiple securities firms are holding mid-term strategy meetings to discuss investment opportunities in the context of global changes, particularly focusing on China's prospects [1][3][10] - The mid-term strategy meetings are seen as a way for securities firms to enhance investor education and promote high-quality development in the capital market [4][5] - The meetings are expected to attract significant investor attention, as they often highlight new capital opportunities [7][10] Group 2 - Securities firms are optimistic about the equity market opportunities in the second half of 2025, with strategies focusing on domestic consumption, technology, and structural opportunities abroad [6][10] - Analysts predict that the A-share market will benefit from the restructuring of international order, with expectations of a stable index and structural bull market [6][10] - The upcoming strategy meetings will also address the impact of external uncertainties and the need for fiscal policies to boost domestic demand [7][10] Group 3 - The mid-term strategy meetings are being held in various formats, including online live broadcasts, to reach a broader audience, particularly younger and tech-savvy investors [5][6] - Major securities firms have scheduled additional strategy meetings for late May and June, indicating a trend of increased engagement with investors [8][9] - The discussions will also cover the implications of geopolitical dynamics on the capital market, with a focus on the comparative advantages of Chinese assets [10]

Core Viewpoint - Huaxi Biological has publicly criticized several securities firms for promoting collagen products and suggesting that hyaluronic acid is "outdated," indicating a defensive stance amid declining performance and market competition [1][2][3] Company Performance - Huaxi Biological started with hyaluronic acid and holds nearly 50% of the global market share, expanding into medical products, skincare, and functional foods [5][6] - Despite maintaining positive growth during the pandemic years of 2020 and 2021, the company's revenue and profit have declined since 2021, with net profits projected to drop from 9.71 billion yuan in 2022 to 1.74 billion yuan in 2024 [10] - The company's market capitalization has plummeted from over 140 billion yuan in 2021 to 25.3 billion yuan as of May 21, 2025 [10] Market Comparison - In contrast, competitors like Juzhi Biological and Jinbo Biological have seen significant growth, with Juzhi's net profits increasing from 1 billion yuan in 2022 to 20.62 billion yuan in 2024, and Jinbo's from 1.09 billion yuan to 7.31 billion yuan in the same period [14] - Both companies have also achieved substantial stock price increases, with market capitalizations of 87.5 billion HKD and 51.1 billion yuan, respectively [14] Industry Dynamics - The rise of collagen products has created a competitive threat to hyaluronic acid, with market trends favoring new ingredients [15][18] - The demand for collagen is expected to exceed supply, with projections indicating a production of 200,000 tons against a demand of over 220,000 tons by 2025 [19] Challenges Ahead - Despite Huaxi's efforts to defend hyaluronic acid, the company faces challenges due to internal management issues and a tarnished brand image, which may hinder future sales growth [20][21] - The company's recent foray into collagen products has not yet shown significant revenue impact, suggesting ongoing struggles in adapting to market changes [21]

Core Viewpoint - The company is actively adjusting its supply chain in response to the 20% tariff challenge and is focusing on high-barrier, high-margin products to maintain its competitive edge in the pharmaceutical industry [2][4]. Company Overview - The company, Jianyou Co., Ltd., is a pharmaceutical enterprise engaged in drug research, production, and sales, with a diverse product pipeline including cardiovascular, neurological, anesthetics, anti-tumor preparations, and high-value sterile injectables [4]. Financial Performance - In Q1 2025, the company reported a main revenue of 885 million yuan, a year-on-year decrease of 11.85% - The net profit attributable to shareholders was 84.71 million yuan, down 52.19% year-on-year - The net profit after deducting non-recurring gains and losses was 75.32 million yuan, a decline of 56.05% - The debt ratio stood at 26.38%, with investment income of 11.13 million yuan and financial expenses of 21.80 million yuan - The gross profit margin was 34.41% [4]. Product Development - The company’s biosimilar drugs are entering a harvest period, with liraglutide expected to receive FDA approval in April 2024, making the company the third globally to enter the market - Sales of adalimumab (Yusimry) have already surpassed 70 million yuan - Collaborations with Tonghua Dongbao and Double Star Pharmaceutical are progressing well, with a focus on insulin and paclitaxel products [4]. Market Strategy - The company views the U.S. market as a significant revenue source and plans to expand into Europe, the Middle East, and Central and South America by 2030, aiming to become a global enterprise [2][4]. Analyst Ratings - In the last 90 days, 9 institutions have given buy ratings for the stock, with an average target price of 19.21 yuan [5]. Profit Forecast - Detailed profit forecasts indicate expected net profits for 2025 ranging from 10.25 billion yuan to 12.18 billion yuan, with projections for 2026 and 2027 also showing growth [7]. Financing Activity - In the past three months, the stock has seen a net inflow of 52.81 million yuan in financing, with an increase in financing balance, while the net inflow of short selling was 953,600 yuan [7].

Core Viewpoint - The article highlights the conflict between Huaxi Biological and several brokerage firms that support Juzi Biological, criticizing the notion that sodium hyaluronate is outdated and emphasizing the ongoing relevance of hyaluronic acid in the beauty and medical aesthetics industry [1][3]. Company Performance - Huaxi Biological's market capitalization has significantly decreased from over 140 billion yuan in 2021 to approximately 25 billion yuan currently, while Juzi Biological's stock has surged nearly 70% in 2024, elevating its founders to the status of the richest individuals in Shaanxi [2]. - In 2024, Huaxi Biological reported its worst performance since going public, with annual revenue of 5.371 billion yuan, a decline of 11.6% year-on-year, and a net profit of 164 million yuan, down 72.27% [2]. - Juzi Biological, in contrast, has shown robust growth since 2019, with 2024 revenue reaching 5.539 billion yuan, a year-on-year increase of 57.17%, and a net profit of 2.062 billion yuan, up 42.06% [2]. Market Trends - The market is increasingly favoring the field of recombinant collagen due to its excellent biocompatibility and biodegradability, with projections indicating that the collagen-based skincare market may surpass that of hyaluronic acid by 2026, with a compound annual growth rate of 52.6% [3]. - Despite the rise of recombinant collagen, hyaluronic acid remains irreplaceable in the medical aesthetics sector, particularly in filling procedures, and Huaxi Biological continues to hold a competitive edge in this area [3]. Industry Dynamics - Several brokerage firms, including Huafu Securities and Debon Securities, have retracted their reports that were criticized by Huaxi Biological, indicating the contentious nature of the market's perception of recombinant collagen [4]. - The development of recombinant collagen is still in its early stages, with high raw material costs and insufficient research on its applications, suggesting that both hyaluronic acid and recombinant collagen may coexist in the market to meet diverse consumer needs [4].

Core Viewpoint - The article discusses the ongoing debate regarding the relevance of hyaluronic acid (HA), with Huaxi Biotech refuting claims that HA is outdated and emphasizing its continued importance in life sciences research [1][2]. Group 1: Market Perspective - Huaxi Biotech directly addresses nine brokerage firms that have published reports suggesting that hyaluronic acid is becoming obsolete, labeling this perspective as a product of "restless capital" creating a false narrative [1]. - The company argues that the rise of the "outdated hyaluronic acid" theory is fundamentally a misrepresentation of a substance that has been central to life sciences for millions of years [1]. Group 2: Research and Development - Since the discovery of HA, the number of related studies has been increasing annually, with a significant surge post-2010, where over 60% of research focuses on cutting-edge areas such as immunity, metabolism, and cell differentiation [1]. - Huaxi Biotech's breakthrough enzyme cutting technology in 2011 has significantly advanced research on hyaluronic acid in fields like cancer, aging, and immunity [1]. Group 3: Future Outlook - The company expresses its commitment to leveraging its foundation in the sugar biology industry to explore deeper realms of life sciences, asserting that hyaluronic acid will always be their starting point [2]. - Huaxi Biotech emphasizes the importance of protecting the industry built over generations and is open to discussions on optimizing scientific and industrial ecosystems [2].